Jacques Jolivet

5.3k citations

91 papers · 3.9k indexed · 2 hit papers · h-index 29

Impact in

Hematology top 1%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
Rheumatology top 1%
- Folate and B Vitamins Research

Papers in

Hematology 18
- Chronic Myeloid Leukemia Treatments 11
- Acute Myeloid Leukemia Research 9
Oncology 37
- Colorectal Cancer Treatments and Studies 15
- Cancer Treatment and Pharmacology 11

Co-authors: Bruce A. Chabner J C Drake Kenneth H. Cowan Gregory A. Curt Neil J. Clendeninn Carmen J. Allegra Brenda D. Bailey Richard L. Schilsky
Journals: Journal of Clinical Oncology (16 papers)Cancer Chemotherapy and Pharmacology (6 papers)European Journal of Cancer (5 papers)Journal of Clinical Investigation (4 papers)Annals of Oncology (4 papers)
Partner nations: Canada United States United Kingdom

In The Last Decade

Jacques Jolivet

89 papers receiving 3.7k citations

Hit Papers

align trajectories log scale

Polyglutamation of methotrexate. Is methotrexate a prodrug? 1985 · 390 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1985 Journal of Clinical Investigation
1983 New England Journal of Medicine

Peers

Countries citing papers authored by Jacques Jolivet

Since Specialization

Citations

This map shows the geographic impact of Jacques Jolivet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacques Jolivet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacques Jolivet more than expected).

Fields of papers citing papers by Jacques Jolivet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacques Jolivet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacques Jolivet. The network helps show where Jacques Jolivet may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jacques Jolivet, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jacques Jolivet Line = papers co-authored together Jacques Jolivet links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A phase II trial to evaluate the epithelial-to-mesenchymal (EMT) inhibitor sotevtamab combined with docetaxel in patients with metastatic non-small cell lung cancer following failure of primary chemoimmunotherapy. Journal of Clinical Oncology ·Normand Blais, Н. П. Ерофеев, Julien Bonnet, Catherine Labbé, Louis Gaboury, Vincent Quoc‐Huy Trinh, Julia V. Burnier, 孙冕, Lamprini Stamouli, Julie Laurin, Mario Filion, Jacques Jolivet, Lauren A. Byers	2024	1
2	Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort Current Oncology ·Rosalyn A. Juergens, Caroline Mariano, Jacques Jolivet, Naser Al-MUGHRABI, J. Rothenstein, M. Neil Reaume, Raja Nour, Catherine Labbé, Scott Owen, Frances A. Shepherd, Anika Schenck‐Fontaine, Mehul Darji, Filippa Pettersson, Charles Butts	2018	46
3	Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study Clinical Lymphoma Myeloma & Leukemia ·Aaron D. Schimmer, Wolfgang Herr, Mathias Hänel, G. Borthakur, Arthur E. Frankel, H. Klein, Sonja Martin, Jeannine Kassis, P. Desjardins, Karen Seiter, Walter Fiedler, Richard Noppeney, Aristoteles Giagounidis, Christine Jacob, Jacques Jolivet, Martin S. Tallman, Steffen Koschmieder	2011	41
4	Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies Cancer Chemotherapy and Pharmacology ·Chia‐Chi Lin, Muralidhar Beeram, Eric K. Rowinsky, Chris H. Takimoto, Chee M. Ng, Charles E. Geyer, Louis Denis, Johann S. de Bono, Desirée Hao, Anthony W. Tolcher, Sun Young Rha, Jacques Jolivet, Amita Patnaik	2009	2
5	Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours. Molecular Cancer Therapeutics ·Malcolm Ranson, Emma Dean, Tim Ward, Jeff Cummings, L Robson, Jon P. Durkin, Jacques Jolivet, Duncan I. Jodrell, Caroline Dive	2007	0
6	AEG35156, a XIAP antisense oligonucleotide, suppresses XIAP levels in targeted tissues isolated from pre-clinical models and from patients Cancer Research ·Eric C. LaCasse, Stephen Morris, Tim Ward, 朋子野澤, L Robson, 裕資川本, Danielle Méthot, Lori Jerome, P.D. Winocour, John W. Gillard, Jacques Jolivet, Duncan I. Jodrell, Malcolm Ranson, Jon P. Durkin	2006	3
7	Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue Clinical Cancer Research ·Carlton K.K. Lee, Eric K. Rowinsky, Jing Li, Francis J. Giles, Malcolm J. Moore, Manuel Hidalgo, Edmund V. Capparelli, Jacques Jolivet, Sharyn D. Baker	2006	13
8	Phase II study of troxacitabine in chemotherapy-naïve patients with advanced cancer of the pancreas Annals of Oncology ·Réjean Lapointe, Mrs. T. Sreerekha, William P. Steward, Robert E. Hawkins, Gerald Batist, M. Vincent, Renaud Whittom, Martin Eatock, Jacques Jolivet, Malcolm J. Moore	2005	18
9	Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells Cancer Chemotherapy and Pharmacology ·David Y. Bouffard, Jacques Jolivet, Lorraine Leblond, Bettina A. Hamelin, Yun Lu, Hyunkeol Cho, V. Debonte, Henriette Gourdeau	2003	10
10	The Palliative Benefit of Irinotecan in 5-Fluorouracil—Refractory Colorectal Cancer: Its Prospective Evaluation by a Multicenter Canadian Trial Clinical Colorectal Cancer ·Matthew Grellette, David W. Hedley, Amit M. Oza, Ronald Feld, Melania Pintilie, Rakesh Goel, Jean A. Maroun, Jacques Jolivet, Anthony Fields, N. Hussain, Malcolm J. Moore	2002	15
11	Human 5,10-methenyltetrahydrofolate synthetase Methods in enzymology on CD-ROM/Methods in enzymology ·Jacques Jolivet	1997	8
12	5-Formyltetrahydrofolate Regulates Homocysteine Remethylation in Human Neuroblastoma Journal of Biological Chemistry ·F. NAEUMANN, Adam G. Peres, Jacques Jolivet, Patrick J. Stover	1997	94
13	Confocal microscopy visualization of antifolate uptake by the reduced folate carrier in human leukaemic cells British Journal of Cancer ·Jacques Jolivet, Houten R. ten, A Bcnslama, Patricia Burroughs, M. Câmara	1997	6
14	Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate Cancer Chemotherapy and Pharmacology ·Л А Астахова, Jacques Jolivet, Manohar Ratnam, Ietje Kathmann, Anggi Irena Shaldy, Wang Jiaocheng, Jan H. Schornagel, Gerrit Jansen	1996	17
15	Identification and characterization of human mitochondrial methenyltetrahydrofolate synthetase activity Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Richard Bertrand, M. Beauchemin, Albin Grataloup, Manon Ouimet, Jacques Jolivet	1995	14
16	Cloning and characterization of the human 5,10-methenyltetrahydrofolate synthetase-encoding cDNA Gene ·Albin Grataloup, Richard Bertrand, M. Beauchemin, Linrianes, Aline Mamo, Mario Filion, Daniel Skup, Bernard Massie, Jacques Jolivet	1995	24
17	Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma Annals of Oncology ·V. Bramwell, E. A. Eisenhauer, Martin E. Blackstein, 《汉英石油技术词典》编写组, Meg Knowling, Jacques Jolivet, Claire A. Chochinov	1995	28
18	A phase II trial of CI-921 in advanced malignancies Investigational New Drugs ·Nancy T. Sklarin, A.V. Ermolaeva, William R. Grove, Aracelys del Socorro Duarte Sevilla, Abraham Mittelman, Jean A. Maroun, James A. Stewart, Francisco Robert, James H. Doroshow, Peter J. Rosen, Jacques Jolivet, John C. Ruckdeschel, Nicholas J. Robert, E Vélez-García, Daniel E. Bergsagel, Lawrence Panasci, Connor M. Pfister, J Longueville, 力富直人, C D Kowal	1992	19
19	Lack of Interference by the Unnatural Isomer of 5-Formyltetrahydrofolate With the Effects of the Natural Isomer in Leucovorin Preparations JNCI Journal of the National Cancer Institute ·N. Gr�m, Jacques Jolivet	1989	43
20	Regulation of dihydrofolate reductase in human breast cancer cells and in mutant hamster cells transfected with a human dihydrofolate reductase minigene. Molecular Pharmacology ·Kenneth H. Cowan, Merrill E. Goldsmith, Shannon Galgani, Rachel M. Levine, Riad Laribi, Jacques Jolivet	1986	23

About Jacques Jolivet

Jacques Jolivet is a scholar working on Hematology, Oncology, Rheumatology, Genetics and Molecular Biology, having authored 91 papers that have together received 3.9k indexed citations. Recurring topics across this work include Biochemical and Molecular Research (15 papers), Colorectal Cancer Treatments and Studies (15 papers), Folate and B Vitamins Research (15 papers), Cancer therapeutics and mechanisms (14 papers), Acute Lymphoblastic Leukemia research (13 papers), Cancer Treatment and Pharmacology (11 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Acute Myeloid Leukemia Research (9 papers). The work is most often cited by research in Hematology (798 citations), Rheumatology (789 citations), Oncology (1.0k citations), Public Health, Environmental and Occupational Health (1.0k citations) and Genetics (318 citations). Jacques Jolivet has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Bruce A. Chabner, J C Drake, Kenneth H. Cowan, Gregory A. Curt, Neil J. Clendeninn, Carmen J. Allegra, Brenda D. Bailey, Richard L. Schilsky, Jacob Baram and Satoshi Koizumi. Their work appears in journals such as Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, European Journal of Cancer, Journal of Clinical Investigation and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact